Cwm LLC Buys 1,358 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Cwm LLC lifted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 415.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,685 shares of the company’s stock after acquiring an additional 1,358 shares during the period. Cwm LLC’s holdings in Syndax Pharmaceuticals were worth $36,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in Syndax Pharmaceuticals by 2,874.6% during the fourth quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after purchasing an additional 3,622 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Syndax Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock worth $305,000 after buying an additional 1,162 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Syndax Pharmaceuticals by 11.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,897 shares of the company’s stock valued at $1,013,000 after acquiring an additional 4,705 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Syndax Pharmaceuticals by 5.3% during the fourth quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock worth $357,000 after acquiring an additional 835 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Syndax Pharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,058 shares of the company’s stock worth $174,000 after acquiring an additional 6,276 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on SNDX shares. Stifel Nicolaus lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $41.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Finally, Citigroup lowered their price objective on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.42.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $21.97 on Friday. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34. The firm has a market cap of $1.87 billion, a P/E ratio of -7.42 and a beta of 1.01. The business’s 50 day moving average price is $22.44 and its 200-day moving average price is $20.17.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. As a group, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.74 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).